Intrinsic value of Supernus Pharmaceuticals - SUPN

Previous Close

$46.50

  Intrinsic Value

$191.02

stock screener

  Rating & Target

str. buy

+311%

Previous close

$46.50

 
Intrinsic value

$191.02

 
Up/down potential

+311%

 
Rating

str. buy

We calculate the intrinsic value of SUPN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  46.26
  40.40
  36.86
  33.67
  30.81
  28.23
  25.90
  23.81
  21.93
  20.24
  18.71
  17.34
  16.11
  15.00
  14.00
  13.10
  12.29
  11.56
  10.90
  10.31
  9.78
  9.30
  8.87
  8.49
  8.14
  7.82
  7.54
  7.29
  7.06
  6.85
  6.67
Revenue, $m
  215
  302
  413
  552
  722
  926
  1,166
  1,444
  1,761
  2,117
  2,513
  2,949
  3,424
  3,937
  4,489
  5,077
  5,700
  6,359
  7,053
  7,780
  8,541
  9,336
  10,164
  11,027
  11,924
  12,857
  13,827
  14,834
  15,881
  16,970
  18,101
Variable operating expenses, $m
 
  142
  194
  260
  340
  435
  548
  679
  827
  995
  1,181
  1,386
  1,609
  1,851
  2,110
  2,386
  2,679
  2,989
  3,315
  3,657
  4,014
  4,388
  4,777
  5,183
  5,604
  6,043
  6,499
  6,972
  7,464
  7,976
  8,507
Fixed operating expenses, $m
 
  64
  65
  67
  68
  70
  72
  74
  76
  77
  79
  81
  83
  85
  88
  90
  92
  94
  97
  99
  102
  104
  107
  109
  112
  115
  118
  121
  124
  127
  130
Total operating expenses, $m
  161
  206
  259
  327
  408
  505
  620
  753
  903
  1,072
  1,260
  1,467
  1,692
  1,936
  2,198
  2,476
  2,771
  3,083
  3,412
  3,756
  4,116
  4,492
  4,884
  5,292
  5,716
  6,158
  6,617
  7,093
  7,588
  8,103
  8,637
Operating income, $m
  54
  96
  154
  226
  314
  421
  546
  692
  858
  1,045
  1,253
  1,482
  1,731
  2,001
  2,291
  2,601
  2,929
  3,276
  3,641
  4,024
  4,425
  4,844
  5,280
  5,735
  6,208
  6,699
  7,210
  7,741
  8,293
  8,867
  9,463
EBITDA, $m
  56
  99
  158
  231
  321
  429
  557
  705
  874
  1,064
  1,276
  1,509
  1,763
  2,038
  2,333
  2,648
  2,982
  3,335
  3,706
  4,096
  4,504
  4,930
  5,374
  5,836
  6,317
  6,818
  7,338
  7,878
  8,440
  9,023
  9,630
Interest expense (income), $m
  0
  0
  2
  4
  7
  10
  14
  18
  24
  30
  37
  44
  53
  62
  72
  82
  93
  105
  118
  131
  145
  160
  175
  191
  208
  225
  243
  262
  281
  301
  322
Earnings before tax, $m
  50
  96
  152
  222
  308
  411
  532
  673
  834
  1,015
  1,216
  1,437
  1,679
  1,940
  2,220
  2,519
  2,836
  3,171
  3,523
  3,893
  4,280
  4,684
  5,105
  5,544
  6,000
  6,474
  6,967
  7,480
  8,012
  8,566
  9,142
Tax expense, $m
  -41
  26
  41
  60
  83
  111
  144
  182
  225
  274
  328
  388
  453
  524
  599
  680
  766
  856
  951
  1,051
  1,156
  1,265
  1,378
  1,497
  1,620
  1,748
  1,881
  2,020
  2,163
  2,313
  2,468
Net income, $m
  91
  70
  111
  162
  225
  300
  389
  491
  609
  741
  888
  1,049
  1,225
  1,416
  1,620
  1,839
  2,070
  2,315
  2,572
  2,842
  3,124
  3,419
  3,727
  4,047
  4,380
  4,726
  5,086
  5,460
  5,849
  6,253
  6,673

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  90
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  310
  309
  423
  565
  739
  948
  1,194
  1,478
  1,802
  2,167
  2,572
  3,018
  3,505
  4,030
  4,594
  5,196
  5,835
  6,509
  7,219
  7,963
  8,742
  9,556
  10,404
  11,286
  12,205
  13,160
  14,152
  15,183
  16,255
  17,369
  18,527
Adjusted assets (=assets-cash), $m
  220
  309
  423
  565
  739
  948
  1,194
  1,478
  1,802
  2,167
  2,572
  3,018
  3,505
  4,030
  4,594
  5,196
  5,835
  6,509
  7,219
  7,963
  8,742
  9,556
  10,404
  11,286
  12,205
  13,160
  14,152
  15,183
  16,255
  17,369
  18,527
Revenue / Adjusted assets
  0.977
  0.977
  0.976
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
  0.977
Average production assets, $m
  13
  18
  24
  32
  42
  54
  68
  84
  102
  123
  146
  171
  199
  228
  260
  294
  331
  369
  409
  451
  495
  541
  590
  640
  692
  746
  802
  860
  921
  984
  1,050
Working capital, $m
  70
  -28
  -38
  -51
  -67
  -86
  -108
  -134
  -164
  -197
  -234
  -274
  -318
  -366
  -417
  -472
  -530
  -591
  -656
  -724
  -794
  -868
  -945
  -1,025
  -1,109
  -1,196
  -1,286
  -1,380
  -1,477
  -1,578
  -1,683
Total debt, $m
  4
  52
  113
  189
  282
  394
  526
  678
  852
  1,047
  1,265
  1,504
  1,764
  2,046
  2,349
  2,671
  3,013
  3,375
  3,755
  4,154
  4,572
  5,008
  5,462
  5,936
  6,428
  6,940
  7,472
  8,024
  8,599
  9,196
  9,817
Total liabilities, $m
  118
  166
  227
  303
  396
  508
  640
  792
  966
  1,161
  1,379
  1,618
  1,878
  2,160
  2,463
  2,785
  3,127
  3,489
  3,869
  4,268
  4,686
  5,122
  5,576
  6,050
  6,542
  7,054
  7,586
  8,138
  8,713
  9,310
  9,931
Total equity, $m
  192
  143
  196
  262
  343
  440
  554
  686
  836
  1,005
  1,194
  1,401
  1,626
  1,870
  2,132
  2,411
  2,707
  3,020
  3,350
  3,695
  4,056
  4,434
  4,827
  5,237
  5,663
  6,106
  6,567
  7,045
  7,542
  8,059
  8,597
Total liabilities and equity, $m
  310
  309
  423
  565
  739
  948
  1,194
  1,478
  1,802
  2,166
  2,573
  3,019
  3,504
  4,030
  4,595
  5,196
  5,834
  6,509
  7,219
  7,963
  8,742
  9,556
  10,403
  11,287
  12,205
  13,160
  14,153
  15,183
  16,255
  17,369
  18,528
Debt-to-equity ratio
  0.021
  0.360
  0.570
  0.720
  0.820
  0.900
  0.950
  0.990
  1.020
  1.040
  1.060
  1.070
  1.090
  1.090
  1.100
  1.110
  1.110
  1.120
  1.120
  1.120
  1.130
  1.130
  1.130
  1.130
  1.140
  1.140
  1.140
  1.140
  1.140
  1.140
  1.140
Adjusted equity ratio
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464
  0.464

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  91
  70
  111
  162
  225
  300
  389
  491
  609
  741
  888
  1,049
  1,225
  1,416
  1,620
  1,839
  2,070
  2,315
  2,572
  2,842
  3,124
  3,419
  3,727
  4,047
  4,380
  4,726
  5,086
  5,460
  5,849
  6,253
  6,673
Depreciation, amort., depletion, $m
  2
  3
  4
  5
  7
  9
  11
  13
  16
  19
  23
  27
  32
  36
  41
  47
  52
  59
  65
  72
  79
  86
  94
  102
  110
  118
  127
  137
  146
  156
  167
Funds from operations, $m
  75
  73
  115
  167
  231
  308
  399
  505
  625
  760
  911
  1,076
  1,257
  1,452
  1,662
  1,885
  2,123
  2,373
  2,637
  2,913
  3,203
  3,505
  3,820
  4,148
  4,490
  4,845
  5,214
  5,597
  5,995
  6,409
  6,840
Change in working capital, $m
  8
  -8
  -10
  -13
  -16
  -19
  -22
  -26
  -29
  -33
  -37
  -41
  -44
  -48
  -51
  -55
  -58
  -61
  -64
  -68
  -71
  -74
  -77
  -80
  -83
  -87
  -90
  -94
  -97
  -101
  -105
Cash from operations, $m
  67
  81
  125
  180
  247
  327
  422
  531
  654
  793
  948
  1,117
  1,301
  1,500
  1,713
  1,940
  2,181
  2,434
  2,701
  2,981
  3,274
  3,579
  3,897
  4,229
  4,573
  4,931
  5,304
  5,691
  6,093
  6,511
  6,945
Maintenance CAPEX, $m
  0
  -2
  -3
  -4
  -5
  -7
  -9
  -11
  -13
  -16
  -19
  -23
  -27
  -32
  -36
  -41
  -47
  -52
  -59
  -65
  -72
  -79
  -86
  -94
  -102
  -110
  -118
  -127
  -137
  -146
  -156
New CAPEX, $m
  -2
  -5
  -6
  -8
  -10
  -12
  -14
  -16
  -18
  -21
  -23
  -25
  -28
  -30
  -32
  -34
  -36
  -38
  -40
  -42
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -58
  -61
  -63
  -66
Cash from investing activities, $m
  -36
  -7
  -9
  -12
  -15
  -19
  -23
  -27
  -31
  -37
  -42
  -48
  -55
  -62
  -68
  -75
  -83
  -90
  -99
  -107
  -116
  -125
  -134
  -144
  -154
  -164
  -174
  -185
  -198
  -209
  -222
Free cash flow, $m
  31
  74
  116
  168
  232
  309
  399
  504
  623
  756
  905
  1,069
  1,246
  1,439
  1,645
  1,865
  2,098
  2,344
  2,603
  2,874
  3,158
  3,454
  3,763
  4,085
  4,420
  4,767
  5,129
  5,505
  5,895
  6,301
  6,723
Issuance/(repayment) of debt, $m
  0
  48
  61
  76
  93
  112
  132
  152
  174
  195
  217
  239
  261
  282
  302
  323
  342
  362
  380
  399
  418
  436
  454
  473
  492
  512
  532
  553
  574
  597
  621
Issuance/(repurchase) of shares, $m
  2
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  2
  48
  61
  76
  93
  112
  132
  152
  174
  195
  217
  239
  261
  282
  302
  323
  342
  362
  380
  399
  418
  436
  454
  473
  492
  512
  532
  553
  574
  597
  621
Total cash flow (excl. dividends), $m
  33
  122
  177
  245
  326
  421
  531
  656
  796
  952
  1,122
  1,308
  1,507
  1,720
  1,947
  2,187
  2,440
  2,705
  2,983
  3,273
  3,575
  3,890
  4,218
  4,558
  4,912
  5,279
  5,661
  6,058
  6,470
  6,898
  7,344
Retained Cash Flow (-), $m
  -104
  -41
  -53
  -66
  -81
  -97
  -114
  -132
  -150
  -169
  -188
  -207
  -226
  -244
  -262
  -279
  -296
  -313
  -329
  -345
  -361
  -377
  -393
  -410
  -426
  -443
  -460
  -479
  -497
  -517
  -537
Prev. year cash balance distribution, $m
 
  90
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  170
  124
  178
  245
  324
  417
  524
  646
  783
  934
  1,101
  1,281
  1,476
  1,685
  1,908
  2,144
  2,392
  2,654
  2,928
  3,214
  3,513
  3,824
  4,149
  4,486
  4,836
  5,201
  5,579
  5,973
  6,382
  6,807
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  163
  114
  155
  202
  251
  303
  354
  404
  450
  490
  523
  547
  561
  566
  560
  545
  521
  489
  451
  408
  363
  317
  272
  228
  188
  152
  120
  92
  70
  51
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

FINANCIAL RATIOS  of  Supernus Pharmaceuticals (SUPN)

Valuation Ratios
P/E Ratio 25.5
Price to Sales 10.8
Price to Book 12.1
Price to Tangible Book
Price to Cash Flow 34.7
Price to Free Cash Flow 35.7
Growth Rates
Sales Growth Rate 46.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 2.1%
Total Debt to Equity 2.1%
Interest Coverage 0
Management Effectiveness
Return On Assets 36.5%
Ret/ On Assets - 3 Yr. Avg. 13.1%
Return On Total Capital 62.5%
Ret/ On T. Cap. - 3 Yr. Avg. 21.1%
Return On Equity 65%
Return On Equity - 3 Yr. Avg. 19%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 94.4%
Gross Margin - 3 Yr. Avg. 94.2%
EBITDA Margin 24.2%
EBITDA Margin - 3 Yr. Avg. 9.8%
Operating Margin 25.1%
Oper. Margin - 3 Yr. Avg. 9.6%
Pre-Tax Margin 23.3%
Pre-Tax Margin - 3 Yr. Avg. 7.6%
Net Profit Margin 42.3%
Net Profit Margin - 3 Yr. Avg. 13.3%
Effective Tax Rate -82%
Eff/ Tax Rate - 3 Yr. Avg. -28.4%
Payout Ratio 0%

SUPN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SUPN stock intrinsic value calculation we used $215 million for the last fiscal year's total revenue generated by Supernus Pharmaceuticals. The default revenue input number comes from 2016 income statement of Supernus Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SUPN stock valuation model: a) initial revenue growth rate of 40.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for SUPN is calculated based on our internal credit rating of Supernus Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Supernus Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SUPN stock the variable cost ratio is equal to 47%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $62 million in the base year in the intrinsic value calculation for SUPN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Supernus Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Supernus Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SUPN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SUPN are equal to 5.8%.

Life of production assets of 6.3 years is the average useful life of capital assets used in Supernus Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SUPN is equal to -9.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $192 million for Supernus Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 52.447 million for Supernus Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Supernus Pharmaceuticals at the current share price and the inputted number of shares is $2.4 billion.

RELATED COMPANIES Price Int.Val. Rating
IPXL Impax Laborato 20.40 5.23  str.sell
CTLT Catalent 43.05 45.16  hold

COMPANY NEWS

▶ Supernus Mourns the Loss of Board Member William Nuerge   [Jan-12-18 03:15PM  GlobeNewswire]
▶ Stocks Generating Improved Relative Strength: Supernus Pharmaceuticals   [Jan-08-18 03:00AM  Investor's Business Daily]
▶ 4 Top Pharmaceutical Stocks for 2018   [Dec-27-17 06:00AM  Investopedia]
▶ Stocks Showing Improved Relative Strength: Supernus Pharmaceuticals   [Dec-13-17 03:00AM  Investor's Business Daily]
▶ Stocks Generating Improved Relative Strength: Supernus Pharmaceuticals   [Dec-11-17 03:00AM  Investor's Business Daily]
▶ Best-In-Class NasdaqGM Growth Stocks   [Dec-10-17 11:02AM  Simply Wall St.]
▶ Why Biotech Sage Therapeutics Is Overvalued   [Nov-17-17 02:43PM  Investopedia]
▶ Supernus tops Street 3Q forecasts   [Nov-06-17 05:49PM  Associated Press]
▶ Supernus Pharma Tops Third-Quarter Sales, Earnings Views   [05:29PM  Investor's Business Daily]
▶ Analysts Latest Recommendations for AbbVie   [Oct-26-17 09:10AM  Market Realist]
▶ Supernus shares decline on drug study change   [Sep-18-17 05:50PM  MarketWatch]
▶ These 4 Biotechs Just Moved Into Buy Zones; Is This Giant Next?   [Sep-01-17 07:45AM  Investor's Business Daily]
▶ Supernus tops Street 2Q forecasts   [12:23AM  Associated Press]
▶ 3 Growth Stocks for Sharp Investors   [Jun-25-17 07:43AM  Motley Fool]
▶ Biotech Stock With 50% Profit Margin Nears Buy Zone   [Jun-20-17 11:31AM  Investor's Business Daily]
▶ Story Stocks from Briefing.com   [Jun-12-17 11:56AM  Briefing.com]
▶ Supernus to Present at Jefferies Healthcare Conference   [Jun-01-17 04:22PM  GlobeNewswire]
▶ Biotech And Pharma Industry And Stock News   [02:59PM  Investor's Business Daily]
▶ Pharma Stock With Triple-Digit Growth Forming Blotchy Base   [May-24-17 12:12PM  Investor's Business Daily]
▶ Top 4 Pharmaceutical Stocks for 2017   [May-19-17 08:00AM  Investopedia]
▶ Want to Get in on Biotech? Check Out These 3 Stocks   [May-16-17 08:32AM  Motley Fool]
▶ Biotech Movers: Anika Up on Strong Analyst Ratings   [May-12-17 09:50AM  TheStreet.com]
▶ Supernus misses Street 1Q forecasts   [May-09-17 04:32PM  Associated Press]
▶ This Biotech Leader Breaks Out, Defying Sector Odds   [Apr-18-17 04:45PM  Investor's Business Daily]
▶ Supernus Drug Gets Label Expansion for Migraines   [Apr-06-17 11:58AM  Investopedia]
▶ 3 Highest Growth Stocks in the Market Today   [Mar-29-17 12:06PM  Motley Fool]
▶ Market Goes on a 'Buy the Dip' Trip   [Mar-27-17 01:17PM  at TheStreet]
Financial statements of SUPN
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.